Abstract
Gastrinomas are neuroendocrine tumors occurring most frequently in the duodenum, followed by the pancreas. They are characterized by the secretion of gastrin, resulting in symptoms that are termed Zollinger-Ellison syndrome. Among functioning pancreatic neuroendocrine tumors, gastrinomas represent one of the most common malignant subtypes. Gastrinomas differ concerning their site of origin and their genetic background. Whereas sporadic gastrinomas occur either in the duodenum or the pancreas, hereditary gastrinomas in the setting of MEN1 are mostly due to multiple and small gastrinomas in the duodenal wall. Sporadic duodenal gastrinomas tend to be smaller and to run a less aggressive clinical course than their pancreatic counterparts. Duodenal gastrinomas in the setting of MEN1 are associated with a less aggressive behavior than sporadic tumors. Histologically, gastrinomas do not exhibit any specific features but are mostly well-differentiated neuroendocrine tumors with a trabecular and pseudoglandular growth pattern, usually corresponding to NET G1 or G2 tumors. In most instances, immunohistochemically they stain positive for gastrin.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Jensen RT, Niederle B, Mitry E et al (2006) Gastrinoma (duodenal and pancreatic). Neuroendocrinology 84(3):173–182
Anlauf M, Garbrecht N, Henopp T et al (2006) Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol 12(34):5440–5446
Gibril F, Jensen RT (2005) Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome. Curr Gastroenterol Rep 7(2):114–121
Kloppel G, Anlauf M (2007) Gastrinoma – morphological aspects. Wien Klin Wochenschr 119(19–20):579–584
Ellison EC, Johnson JA (2009) The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg 46(1):13–106
Roy PK, Venzon DJ, Shojamanesh H et al (2000) Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) 79(6):379–411
Zollinger EH, Ellison RM (1955) Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 142(4):709–723; discussion 724–748
Oberg K (2010) Pancreatic endocrine tumors. Semin Oncol 37(6):594–618
Metz DC, Jensen RT (2008) Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135(5):1469–1492
Gibril F, Schumann M, Pace A et al (2004) Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 83(1):43–83
Jensen RT, Berna MJ, Bingham DB et al (2008) Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 113(7 Suppl):1807–1843
Corleto VD, Annibale B, Gibril F et al (2001) Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther 15(10):1555–1561
Berna MJ, Hoffmann KM, Serrano J et al (2006) Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 85(6):295–330
Banasch M, Schmitz F (2007) Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors. Wien Klin Wochenschr 119(19–20):573–578
Osefo N, Ito T, Jensen RT (2009) Gastric acid hypersecretory states: recent insights and advances. Curr Gastroenterol Rep 11(6):433–441
Kulke MH, Anthony LB, Bushnell DL et al (2010) NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39(6):735–752
Arnold R (2007) Diagnosis and differential diagnosis of hypergastrinemia. Wien Klin Wochenschr 119(19–20):564–569
Vinik AI, Woltering EA, Warner RR et al (2010) NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 39(6):713–734
O’Toole D, Grossman A, Gross D et al (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers. Neuroendocrinology 90(2):194–202
Niederle B (2007) Hypergastrinemia – diagnosis and treatment. Wien Klin Wochenschr 119(19–20):561–563
Goldman JA, Blanton WP, Hay DW et al (2009) False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol 7(5):600–602
Weber HC, Venzon DJ, Lin JT et al (1995) Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 108(6):1637–1649
Yu F, Venzon DJ, Serrano J et al (1999) Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 17(2):615–630
Pape UF, Jann H, Muller-Nordhorn J et al (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113(2):256–265
Gibril F, Venzon DJ, Ojeaburu JV et al (2001) Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 86(11):5282–5293
Maton PN, Gardner JD, Jensen RT (1986) Cushing’s syndrome in patients with the Zollinger-Ellison syndrome. N Engl J Med 315(1):1–5
Cadiot G, Vuagnat A, Doukhan I et al (1999) Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d’Etude des Neoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d’Etude du Syndrome de Zollinger-Ellison (GRESZE). Gastroenterology 116(2):286–293
Norton JA, Jensen RT (2004) Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 240(5):757–773
Goh BK, Chow PK, Tan YM et al (2011) Validation of five contemporary prognostication systems for primary pancreatic endocrine neoplasms: results from a single institution experience with 61 surgically treated cases. ANZ J Surg 81(1–2):79–85
Fendrich V, Waldmann J, Bartsch DK et al (2009) Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol 6(7):419–428
Tonelli F, Fratini G, Nesi G et al (2006) Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg 244(1):61–70
Grobmyer SR, Vogel SB, McGuigan JE et al (2009) Reoperative surgery in sporadic Zollinger-Ellison Syndrome: longterm results. J Am Coll Surg 208(5):718–722; discussion 722–724
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Schmitt, A.M., Blank, A., Perren, A. (2015). Gastrinoma. In: La Rosa, S., Sessa, F. (eds) Pancreatic Neuroendocrine Neoplasms. Springer, Cham. https://doi.org/10.1007/978-3-319-17235-4_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-17235-4_12
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-17234-7
Online ISBN: 978-3-319-17235-4
eBook Packages: MedicineMedicine (R0)